Is HYPR or FEMY more profitable?

Hyperfine has a net margin of -210.75% compared to Femasys' net margin of -534.36%. Hyperfine's return on equity of -97.88% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -210.75% -97.88% -61.81% Femasys -534.36% -225.97% -74.68%

Does the media refer more to HYPR or FEMY?

In the previous week, Hyperfine had 2 more articles in the media than Femasys. MarketBeat recorded 3 mentions for Hyperfine and 1 mentions for Femasys. Femasys' average media sentiment score of 0.00 beat Hyperfine's score of -0.02 indicating that Femasys is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is FEMY or LUNG more profitable?

Pulmonx has a net margin of -55.03% compared to Femasys' net margin of -534.36%. Pulmonx's return on equity of -96.66% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -534.36% -225.97% -74.68% Pulmonx -55.03% -96.66% -38.32%

Does the media favor FEMY or LUNG?

In the previous week, Pulmonx had 1 more articles in the media than Femasys. MarketBeat recorded 2 mentions for Pulmonx and 1 mentions for Femasys. Pulmonx's average media sentiment score of 0.42 beat Femasys' score of 0.00 indicating that Pulmonx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pulmonx 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, FEMY or CVRX?

Femasys has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.29M 9.44 -$18.63M -$3.53 N/A CVRx $56.65M 1.28 -$53.31M -$1.98 N/A

Is FEMY or CVRX more profitable?

CVRx has a net margin of -84.93% compared to Femasys' net margin of -534.36%. CVRx's return on equity of -152.35% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -534.36% -225.97% -74.68% CVRx -84.93% -152.35% -50.93%

Does the media favor FEMY or CVRX?

In the previous week, CVRx had 7 more articles in the media than Femasys. MarketBeat recorded 8 mentions for CVRx and 1 mentions for Femasys. CVRx's average media sentiment score of 0.01 beat Femasys' score of 0.00 indicating that CVRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CVRx 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, FEMY or RNXT?

RenovoRx has lower revenue, but higher earnings than Femasys. RenovoRx is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.29M 9.44 -$18.63M -$3.53 N/A RenovoRx $1.12M 65.68 -$11.17M -$0.31 N/A

Is FEMY or RNXT more profitable?

Femasys has a net margin of -534.36% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -534.36% -225.97% -74.68% RenovoRx -621.71% -135.11% -101.91%

Does the media favor FEMY or RNXT?

In the previous week, Femasys and Femasys both had 1 articles in the media. RenovoRx's average media sentiment score of 1.92 beat Femasys' score of 0.00 indicating that RenovoRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RenovoRx 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, FEMY or NRXS?

NeurAxis has higher revenue and earnings than Femasys. NeurAxis is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.29M 9.44 -$18.63M -$3.53 N/A NeurAxis $5.32M 17.27 -$14.63M -$0.78 N/A

Is FEMY or NRXS more profitable?

NeurAxis has a net margin of -492.76% compared to Femasys' net margin of -534.36%. NeurAxis' return on equity of 0.00% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -534.36% -225.97% -74.68% NeurAxis -492.76% N/A -641.25%

Does the media prefer FEMY or NRXS?

In the previous week, Femasys and Femasys both had 1 articles in the media. Femasys' average media sentiment score of 0.00 equaled NeurAxis'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeurAxis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Femasys (FEMY) Competitors

$2.58 +0.02 (+0.78%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.55 -0.03 (-1.16%)

As of 05:21 AM Eastern

Compare

FEMY vs. HYPR, LUNG, CVRX, RNXT, and NRXS

Should you buy Femasys stock or one of its competitors? Femasys's main competitors and comparable companies include Hyperfine (HYPR), Pulmonx (LUNG), CVRx (CVRX), RenovoRx (RNXT), and NeurAxis (NRXS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Femasys compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Femasys has lower revenue, but higher earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	7.35	-$35.57M	-$0.38	N/A
Femasys	$2.29M	9.44	-$18.63M	-$3.53	N/A

Hyperfine currently has a consensus price target of $2.03, indicating a potential upside of 157.38%. Femasys has a consensus price target of $50.00, indicating a potential upside of 1,837.98%. Given Femasys' stronger consensus rating and higher probable upside, analysts clearly believe Femasys is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Hyperfine has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Femasys has a beta of -2.07, suggesting that its stock price is 307% less volatile than the broader market.

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by company insiders. Comparatively, 7.8% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Hyperfine has a net margin of -210.75% compared to Femasys' net margin of -534.36%. Hyperfine's return on equity of -97.88% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-210.75%	-97.88%	-61.81%
Femasys	-534.36%	-225.97%	-74.68%

In the previous week, Hyperfine had 2 more articles in the media than Femasys. MarketBeat recorded 3 mentions for Hyperfine and 1 mentions for Femasys. Femasys' average media sentiment score of 0.00 beat Hyperfine's score of -0.02 indicating that Femasys is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Hyperfine beats Femasys on 8 of the 15 factors compared between the two stocks.

How does Femasys compare to Pulmonx?

Femasys (NASDAQ:FEMY) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Femasys has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	9.44	-$18.63M	-$3.53	N/A
Pulmonx	$87.44M	0.98	-$54M	-$1.16	N/A

65.3% of Femasys shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 7.8% of Femasys shares are owned by insiders. Comparatively, 7.5% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pulmonx has a net margin of -55.03% compared to Femasys' net margin of -534.36%. Pulmonx's return on equity of -96.66% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
Pulmonx	-55.03%	-96.66%	-38.32%

Femasys presently has a consensus target price of $50.00, suggesting a potential upside of 1,837.98%. Pulmonx has a consensus target price of $7.67, suggesting a potential upside of 283.33%. Given Femasys' higher possible upside, analysts clearly believe Femasys is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Pulmonx had 1 more articles in the media than Femasys. MarketBeat recorded 2 mentions for Pulmonx and 1 mentions for Femasys. Pulmonx's average media sentiment score of 0.42 beat Femasys' score of 0.00 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulmonx	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Femasys has a beta of -2.07, indicating that its share price is 307% less volatile than the broader market. Comparatively, Pulmonx has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Summary

Pulmonx beats Femasys on 9 of the 14 factors compared between the two stocks.

How does Femasys compare to CVRx?

Femasys (NASDAQ:FEMY) and CVRx (NASDAQ:CVRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

CVRx has a net margin of -84.93% compared to Femasys' net margin of -534.36%. CVRx's return on equity of -152.35% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
CVRx	-84.93%	-152.35%	-50.93%

65.3% of Femasys shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 7.8% of Femasys shares are owned by company insiders. Comparatively, 16.6% of CVRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Femasys has a beta of -2.07, suggesting that its share price is 307% less volatile than the broader market. Comparatively, CVRx has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Femasys has higher earnings, but lower revenue than CVRx. CVRx is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	9.44	-$18.63M	-$3.53	N/A
CVRx	$56.65M	1.28	-$53.31M	-$1.98	N/A

Femasys presently has a consensus target price of $50.00, suggesting a potential upside of 1,837.98%. CVRx has a consensus target price of $4.30, suggesting a potential upside of 58.09%. Given Femasys' stronger consensus rating and higher probable upside, equities analysts plainly believe Femasys is more favorable than CVRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
CVRx	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, CVRx had 7 more articles in the media than Femasys. MarketBeat recorded 8 mentions for CVRx and 1 mentions for Femasys. CVRx's average media sentiment score of 0.01 beat Femasys' score of 0.00 indicating that CVRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CVRx	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CVRx beats Femasys on 10 of the 16 factors compared between the two stocks.

How does Femasys compare to RenovoRx?

Femasys (NASDAQ:FEMY) and RenovoRx (NASDAQ:RNXT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Femasys presently has a consensus target price of $50.00, suggesting a potential upside of 1,837.98%. RenovoRx has a consensus target price of $8.50, suggesting a potential upside of 421.47%. Given Femasys' higher possible upside, analysts clearly believe Femasys is more favorable than RenovoRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

65.3% of Femasys shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 7.8% of Femasys shares are held by insiders. Comparatively, 9.4% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

RenovoRx has lower revenue, but higher earnings than Femasys. RenovoRx is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	9.44	-$18.63M	-$3.53	N/A
RenovoRx	$1.12M	65.68	-$11.17M	-$0.31	N/A

Femasys has a beta of -2.07, meaning that its stock price is 307% less volatile than the broader market. Comparatively, RenovoRx has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

In the previous week, Femasys and Femasys both had 1 articles in the media. RenovoRx's average media sentiment score of 1.92 beat Femasys' score of 0.00 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RenovoRx	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Femasys has a net margin of -534.36% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
RenovoRx	-621.71%	-135.11%	-101.91%

Summary

RenovoRx beats Femasys on 9 of the 16 factors compared between the two stocks.

How does Femasys compare to NeurAxis?

Femasys (NASDAQ:FEMY) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

Femasys currently has a consensus target price of $50.00, indicating a potential upside of 1,837.98%. NeurAxis has a consensus target price of $13.00, indicating a potential upside of 77.84%. Given Femasys' higher probable upside, research analysts clearly believe Femasys is more favorable than NeurAxis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Femasys and Femasys both had 1 articles in the media. Femasys' average media sentiment score of 0.00 equaled NeurAxis'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeurAxis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Femasys has a beta of -2.07, suggesting that its stock price is 307% less volatile than the broader market. Comparatively, NeurAxis has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

65.3% of Femasys shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 7.8% of Femasys shares are owned by company insiders. Comparatively, 21.1% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NeurAxis has a net margin of -492.76% compared to Femasys' net margin of -534.36%. NeurAxis' return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
NeurAxis	-492.76%	N/A	-641.25%

NeurAxis has higher revenue and earnings than Femasys. NeurAxis is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	9.44	-$18.63M	-$3.53	N/A
NeurAxis	$5.32M	17.27	-$14.63M	-$0.78	N/A

Summary

NeurAxis beats Femasys on 9 of the 14 factors compared between the two stocks.

Get Femasys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEMY vs. The Competition

Export

Metric	Femasys	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.44M	$5.58B	$7.31B	$13.29B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	-0.73	25.27	274.09	25.69
Price / Sales	9.44	71.58	642.55	79.71
Price / Cash	N/A	33.02	77.80	52.76
Price / Book	1.28	5.78	10.47	6.32
Net Income	-$18.63M	$151.55M	$3.49B	$359.73M
7 Day Performance	1.18%	0.01%	-0.68%	0.17%
1 Month Performance	-13.42%	-3.51%	-3.18%	-3.27%
1 Year Performance	-63.49%	6.37%	15.12%	5.58%

Femasys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEMY Femasys	2.8055 of 5 stars	$2.58 +0.8%	$50.00 +1,838.0%	-62.5%	$21.44M	$2.29M	N/A	54	News Coverage
HYPR Hyperfine	2.1013 of 5 stars	$0.80 -0.3%	$2.03 +153.8%	-45.9%	$84.97M	$16.54M	N/A	190	Analyst Forecast
LUNG Pulmonx	3.1399 of 5 stars	$1.91 -3.0%	$7.67 +301.4%	+9.9%	$82.03M	$87.44M	N/A	250	Positive News
CVRX CVRx	4.1155 of 5 stars	$3.00 flat	$5.30 +76.7%	-63.5%	$79.93M	$61.19M	N/A	160	Analyst Forecast
RNXT RenovoRx	3.4703 of 5 stars	$1.72 +1.8%	$8.50 +394.2%	+32.5%	$77.62M	$1.98M	N/A	6	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEMY) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Femasys (FEMY) Competitors